# Linperlisib

Source: https://onco.cc/drugs/linperlisib/  
OnCo record `linperlisib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.

## Summary

Linperlisib (YY-20394) was developed by Shanghai Yingli Pharmaceutical. The NMPA gave it conditional approval in November 2022 for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, on a single-arm phase 2 trial with an overall response rate near 80 percent. It is the first PI3K inhibitor developed in China to reach approval.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Yinlijia
- Tags: china; nmpa-approved
- Code: YY-20394
- Modality: Oral PI3K-delta inhibitor
- Mechanism: Blocks the delta form of PI3K, a signalling enzyme B-cell lymphomas depend on for survival.
- Approvals: CN 2022: Relapsed or refractory follicular lymphoma after two or more lines, conditional

## Sources

- ClinicalTrials.gov: trials of linperlisib: https://clinicaltrials.gov/search?intr=YY-20394

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- companies: [Shanghai Yingli Pharmaceutical](https://onco.cc/companies/shanghai-yingli/)

---
JSON: https://onco.cc/api/v1/entities/linperlisib.json